Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations
about
sameAs
Genome-wide association studies and the clinic: a focus on breast cancerLi-fraumeni syndromePolo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistanceChk2 phosphorylation of BRCA1 regulates DNA double-strand break repairSensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastomaPALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility geneMultidisciplinary meeting on male breast cancer: summary and research recommendationsGenome-wide association study identifies novel breast cancer susceptibility lociVariation of breast cancer risk among BRCA1/2 carriers.A census of human cancer genesAnalysis of PALB2/FANCN-associated breast cancer familiesDuctal approaches to assessment and management of women at high risk for developing breast cancerFrequency of CHEK2 mutations in a population based, case-control study of breast cancer in young womenMolecular tumor profiling: translating genomic insights into clinical advancesFrequency of CHEK2*1100delC in New York breast cancer cases and controlsCancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation statusFamilial breast cancer and the hCHK2 1100delC mutation: assessing cancer riskThe Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancerTP53-binding protein variants and breast cancer risk: a case-control studyGenetic polymorphisms in DPF3 associated with risk of breast cancer and lymph node metastases.Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyGenetic causes of cancer predisposition in children and adolescentsOptimal delivery of male breast cancer follow-up care: improving outcomesThe genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevanceCHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11(p110)NFBD1, a novel nuclear protein with signature motifs of FHA and BRCT, and an internal 41-amino acid repeat sequence, is an early participant in DNA damage responseNFBD1/KIAA0170 is a chromatin-associated protein involved in DNA damage signaling pathwaysGermline mutations in RAD51D confer susceptibility to ovarian cancerThe variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutationsPathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutationsThe CHEK2 gene and inherited breast cancer susceptibilityEDD mediates DNA damage-induced activation of CHK2Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forksMosaic PPM1D mutations are associated with predisposition to breast and ovarian cancerGermline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian PopulationCancer evolution and individual susceptibilityGerm line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasmsDeep congenic analysis identifies many strong, context-dependent QTLs, one of which, Slc35b4, regulates obesity and glucose homeostasis
P2860
Q22064616-16A8D5E5-AB36-406B-9230-2495153551A0Q22241780-524E7099-1E39-4E5C-90DF-E6AFA7E6AB26Q24337413-ACECAF93-5711-46EA-908F-77C03184681EQ24599364-FD58FA88-4592-4FE9-AC8A-58DB63797654Q24603375-49A2E3C1-A239-40F4-90DD-9930F337B636Q24611398-7347D302-6CBA-4EF2-A502-5F0CA47B1881Q24615080-EC67F8D0-4D74-4284-B2DC-CCA301119C11Q24631800-272D2F2E-1538-4148-8267-1AA9067AB52AQ24645441-5685615B-969F-40C3-9DDF-6F5653D00E01Q24646346-A64FE0A0-79B8-41DA-A33C-2FDFE1C0A2A4Q24647081-795F25DD-4112-4B05-AC04-70E638AF4EAAQ24683771-7AAFE3B6-B5D1-4477-88BD-43602AD04A3BQ24794407-E74CD0EE-8223-487D-91D0-9D1E0F719536Q24795977-081C4460-59C7-4D07-A30E-EF469DEFD06FQ24797250-186E5752-5113-44F6-A8FC-F4BD2355FEDAQ24798279-B90ABFCA-9EE1-48FF-A795-A4771B247EB1Q24802534-868816B7-EBD0-49C6-BD18-F5E8FE98E2C6Q24803409-23964737-949B-452D-BA1B-20EC2D94C4DDQ24806109-09015011-5894-44DE-8BC3-D006D2001170Q24810703-D7B32A26-60A2-409A-A0EC-6043FD1BA64EQ24814744-9AD3F0B2-AAB7-446D-A03E-DF509EC0087EQ25257392-51970F75-05A7-41A3-B1D3-D2D72A10342AQ26745686-111F78CD-40FD-49F4-B508-A5754E998AE6Q26770339-0FF2FE9D-D17B-4A94-B5ED-2BBD943AAABCQ26773195-036E9FB0-C580-444A-933E-D480EAAD5E44Q28074414-C9FF63F5-79DE-4A6D-BF9B-7C8186E6BC67Q28118922-FB1ADC24-87F1-4B13-BECD-A644CBCAB198Q28217141-F3FBBA8C-A706-4FDD-9633-77E1BE4DAEECQ28218966-065F044E-0D19-43B5-896D-90454151CBFBQ28245028-5245F1FE-A539-4638-8882-8425F307DA71Q28264156-BB535234-2162-46D0-9E28-883190ED6F9FQ28265304-D7A133E2-68C9-4986-B78A-8D74D692916FQ28265315-4245C3A1-FE1F-42CF-A398-F47047FAC52CQ28271191-C3CDFDB8-47D6-43EC-92E5-53B074748F04Q28294399-11227F0D-6435-4139-ABC4-2CFDA11957A0Q28388006-12786324-F2E1-46B1-A2D4-88D9C0E418CEQ28389268-0513D66D-3410-46D5-AF3D-F6716870F459Q28389946-A0103186-7617-422A-B8F3-D72432341996Q28392728-0C63FBD8-A369-4ACD-8F9D-3528C3E58006Q28512493-66995BF2-84D9-43C1-A54D-E24816E5DF02
P2860
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Low-penetrance susceptibility ...... rs of BRCA1 or BRCA2 mutations
@ast
Low-penetrance susceptibility ...... rs of BRCA1 or BRCA2 mutations
@en
Low-penetrance susceptibility ...... rs of BRCA1 or BRCA2 mutations
@nl
type
label
Low-penetrance susceptibility ...... rs of BRCA1 or BRCA2 mutations
@ast
Low-penetrance susceptibility ...... rs of BRCA1 or BRCA2 mutations
@en
Low-penetrance susceptibility ...... rs of BRCA1 or BRCA2 mutations
@nl
prefLabel
Low-penetrance susceptibility ...... rs of BRCA1 or BRCA2 mutations
@ast
Low-penetrance susceptibility ...... rs of BRCA1 or BRCA2 mutations
@en
Low-penetrance susceptibility ...... rs of BRCA1 or BRCA2 mutations
@nl
P2093
P50
P3181
P356
P1433
P1476
Low-penetrance susceptibility ...... rs of BRCA1 or BRCA2 mutations
@en
P2093
Anja de Snoo
Ans van den Ouweland
Barbara Weber
Carel Meijers
Carina Bartels
Catherine Phelan
Csilla Szabo
David Goldgar
Deborah Thompson
Ellen Crepin
P2888
P3181
P356
10.1038/NG879
P407
P50
P577
2002-05-01T00:00:00Z